What type of study is this?

This is a Quantitative Study study.

October 2, 2025Open Access

Supplementary Figure S2 from Association of Homologous Recombination Repair Alterations with Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Key Points

Patients with ATM alterations showed distinct outcomes, impacting overall survival in metastatic prostate cancer.
Time to castration-resistance differed significantly between ATMalt and no ATMalt in patients receiving ARPI treatment.
Outcomes for both overall survival and time to castration-resistance were analyzed across treatment types using adjusted hazard ratios.
These findings suggest a crucial role of homologous recombination repair alterations in determining treatment responses.

Abstract

Outcomes on ARPI or taxane by ATMalt status. Outcomes for ATMalt vs. no ATMalt are shown on ADT + ARPI for (A) TTCR and (C) OS. Outcomes for ATMalt vs. no ATMalt are shown on ADT + taxane for (B) TTCR and (D) OS. Abbreviations: aHR, adjusted hazard ratio; alt, alteration; ARPI, androgen receptor pathway inhibitor; CI, confidence interval; CRPC, castrate-resistant prostate cancer; doce, docetaxel; TTCR, time to castrate-resistance; OS, overall survival.

Read Full Paperexternally

AI से पूछें

Bookmark

View Full Paper